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EPOS2020: development strategy and goals 
Abstract 
Background: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the 
way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration 
of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treat-
ment modalities, and formulating clear recommendations based on all available evidence. 
Methodology: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six 
key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: 
scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; 
editorial independence.
Results: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new 
stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded 
areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-
based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommenda-
tions. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility.
Conclusion: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned me-
thodology and dissemination strategies for the latest version of this influential guideline.
Key words: rhinosinusitis, EPOS, methodology, recommendations, stakeholders, patients, nasal polyps, upper respiratory tract 
infection, asthma 
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Rhinosinusitis is a common condition in most of the world, 
leading to a significant burden on society in terms of healthcare 
consumption and productivity loss (1-4).
Acute rhinosinusitis (ARS) has a 1-year prevalence of 6-15% 
and is usually the consequence of a viral common cold. ARS is 
usually a self-limiting disease but serious complications leading 
to life threatening situations and even death have been descri-
bed (5). It is one of the most common reasons for prescription of 
antibiotics and proper management is extremely pertinent in 
the context of the global crisis of antibiotics (6). Chronic rhinosi-
nusitis (CRS) is a significant health problem and affects 5-12% of 
the general population (1, 2, 7, 8). CRS can present with (CRSwNP) or 
without nasal polyps (CRSsNP). The first group in particular often 
needs recurrent surgical procedures and systemic treatment 
with corticosteroids and is associated with severe asthma (9-14). 
The European Position Paper on Rhinosinusitis (EPOS 2020) will 
be the latest in the EPOS series of guidelines on rhinosinusitis 
from an international cohort of experts in the field.
The first European Position Paper on Rhinosinusitis and Nasal 
Polyps (EP3OS) (15, 16)  was published in 2005, and was soon follo-
wed by EP3OS 2007 (17, 18) in response to the first position paper’s 
extremely positive reception and the growing body of research 
in this area. 
The latest European Position Paper on Rhinosinusitis, EPOS 2012 
(19, 20) was hugely successful and widely cited worldwide. It deli-
vered a comprehensive review of the key topics in an accessible 
format with clear research priorities. 
EPOS has inspired researchers to use standard definitions of 
disease, study the epidemiology and management of ARS and 
CRS, reduce unnecessary (mainly antibiotic) treatment and form 
new collaborations to answer unmet research questions (9, 21-26).  
EPOS2020 will build on this success. We plan to utilize a com-
bination of methodologies to expand on the existing research 
base and explore areas not covered in the previous guidelines. 
This article outlines our development strategies in order to 
achieve these goals based on the AGREE II framework (27), a tool 
which aims to ensure consistency in quality of clinical practice 
guidelines, provide a methodological strategy for the develop-
ment of guidelines and clarify what and how information ought 
to be reported in guidelines.
Scope and purpose
The core objective of the EPOS2020 guideline is to provide real, 
practical, collaborative management strategies for rhinosinu-
sitis based on a combination of evidence based and clinically 
relevant research. We aim to build on the success of previous 
EPOS position papers, in particular EPOS2012, which was widely 
acclaimed for its presentation of science translated into clinical 
care and treatment of disease. EPOS2012 can also be credited 
with the sharp rise in understanding of separate endotypes in 
CRS and the relationship to different phenotypes. This know-
ledge will lead to significant adjustments in the management of 
CRS, especially in CRSwNP (28, 29).
All topics from EPOS2012 will be revised and updated based on 
the latest research and evidence. Areas that EPOS2020 will ex-
plore in more detail than in previous guidelines are summarised 
in Table 1. In particular, evolving treatment modalities especially 
with biologicals, need reevaluation in terms of current treatment 
algorithms (30, 31).
The EPOS 2020 guideline will apply to the adult and paediatric 
patient population with ARS (viral / common cold, post-viral, 
bacterial), CRSsNP and CRSwNP. It will furthermore be applicable 
to patients with associated conditions, such as allergic rhinitis, 
asthma, bronchiectasis, chronic obstructive pulmonary disease 
(COPD), severe upper airway disease and rare diseases including 
primary ciliary dyskinesia (PCD), cystic fibrosis, vasculitis and 
immune deficiencies. EPOS2020 will also address patients with 
associated symptoms, such as facial pain / pressure, sleep disor-
ders, smell disorders and odontogenic problems, many of which 
are principal symptoms in the diagnosis of rhinosinusitis.
Stakeholder involvement 
The EPOS2020 guideline development group is made up of 
international ENT / rhinology specialists representing a range of 
Table 1. New and expanded areas of research for EPOS2020.
Developments in understanding the pathophysiology of rhinosinu-
sitis, their translation into clinics (endotyping), with emphasis on the 
consequences for the use of biologicals.
Role of biologicals cost effectiveness / cost benefit analysis, efficacy 
versus safety
Surgical management of both acute and chronic rhinosinusitis (adult 
and paediatric) with finer details and new technologies; extent of 
surgery; revision surgery.
Genome / epigenome results for rhinosinusitis
Precision medicine in rhinosinusitis
Emergencies in rhinosinusitis
Systemic diseases affecting the nose and paranasal sinuses
Importance of loss of smell in diagnosis / severity / control of disease
Sleep problems in patients with CRS
Integrated care pathways / collaboration and consultation with other 
specialties
The ‘difficult to treat patient’
Molecular allergology in the diagnosis of rhinosinusitis 
Mobile Health technology in the management of rhinosinusitis
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clinical trials.
For all topics we will search MEDLINE (either via OVID or via 
PubMed) and EMBASE (via OVID or embase.com). In the case 
of (controlled) trials we will also search the Cochrane Central 
Register of Controlled Trials, the Cochrane Database of Systemic 
Reviews, and clinical trial registers including www.clinicaltrials.
gov, the WHO International Clinical Trials Registry Platform (IC-
TRP) and www.trialregistration.org. Depending on the topic and 
/or the available evidence we will also search Web of Science, 
Google Scholar and Google. There will be no language or date 
restriction. Complete search strategies will be shown in appen-
dices to the final document.
A drawback of EBM methodology is that it relies heavily on RCTs, 
which are a limited way of looking at the bigger picture. This 
methodology is also difficult to apply to certain areas of research 
for EPOS2020, for example when exploring the role of surgery 
in rhinosinusitis. Most surgical evidence is based on observatio-
nal studies, with recent research showing some justification for 
incorporating non-randomized studies (35, 36).
Delphi trials will be directed to ENT / rhinology specialists / pri-
mary practitioners to reach expert consensus on areas including 
(but not limited to) diagnostics, certain treatments for acute rhi-
nosinusitis, and in CRS, appropriate medical therapy and surgery 
(and technique to use) in adult and paediatric rhinosinusitis, as 
well as adjunctive techniques such as image guidance. Inclusion 
and exclusion criteria for selecting the evidence will differ for 
each section of the EPOS2020 guideline. When enough RCTs 
with sufficient patient numbers are available, other evidence 
will not primarily be included. In all other situations all forms 
of evidence, case control, cohort studies, real-life studies and 
Delphi rounds will be used. GRADE (Grading of Recommenda-
tions Assessment, Development and Evaluation, http://www.
gradeworkinggroup.org/) will be used whenever possible.
In-depth criteria for each section will be included in appendices 
to the final EPOS2020 document, see EPOS2012 for examples (19). 
Details of the strengths and limitations of the body of evidence 
geographical locations and specialties, as well as other experts 
interested in the field (including allergologists, pulmonologists, 
GPs, pharmacists, paediatricians, microbiologists) and patient 
representatives. The group will also include key methodology 
experts. 
Our primary target users will be ENT / rhinology specialists, 
providing them with an up-to-date review of the latest research 
and clear diagnostic and treatment strategies and recommenda-
tions. For non-ENT primary practitioners, such as GPs (including 
family and emergency physicians), pharmacists and paediatrici-
ans our aim is to inform them of the latest research and recom-
mendations and provide clear care pathways. Other specialists 
including allergologists / immunologists, pulmonologists, 
doctors of internal medicine and secondary practitioners such 
as nurses will be provided with clear, unambiguous definitions 
of the terminology and information on the latest research and 
recommendations. 
Patient involvement will be a defining element of EPOS2020, 
and this is reflected by the inclusion of key patient represen-
tatives in the development group, along with a dissemination 
strategy which will target users beyond the immediate clinical 
sphere. The initiatives started within EUFOREA that will find a so-
lid base in EPOS2020 and will help to better inform patients and 
further empower them to seek optimal help in the management 
of their disease (32-34). 
The position paper will provide guidelines for relevant go-
vernment bodies, national and international drug agencies 
[e.g. the European Medicines Agency (EMA) and the Food and 
Drug Administration (FDA) in the USA] and scientific societies, 
particularly regarding the use of terminology, definitions and 
classification for clinical trials. In addition, EPOS2020 will be an 
important tool for insurance companies and payers, and will act 
as a key reference tool for national and international mass media 
providing disease information to the general population.
Rigour of development
EPOS2020 will use mixed methodologies to incorporate grades 
of evidence and grades of expert opinion / common consensus. 
The aim is to combine expert opinion with methodological 
back-up, to be as inclusive as possible and to be clear in our 
definitions.
Methodology
We will use evidence-based medicine (EBM) methodologies to 
search for our evidence, incorporating randomized controlled 
trials (RCTs) with ‘Real World Experience (RWE) – observational 
studies (surgery) / real-life studies, and using network analysis 
and meta-analysis of systematic reviews to combine results from 
Table 2. Key considerations for EPOS2020 literature review.
Study methodology limitations 
Appropriateness / relevance of primary and secondary outcomes 
Consistency of results across studies 
Direction of results across studies 
Magnitude of benefit versus magnitude of harm 
Applicability to practice context
Directions for future research
Taken from the AGREE II guidelines (27).
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and the risk of bias will also be laid out in full. Table 2 shows the 
key factors which will be considered for all studies and reviews 
undertaken for EPOS2020, according to AGREE-II guidelines (27).
Recommendations
Recommendations will be formulated based on review and 
analysis of the latest research into rhinosinusitis, combined with 
expert opinion. Using Delphi methodology, we will ensure that 
expert opinion is reached by common consensus in areas where 
the evidence base is limited. In this way we will be able to incor-
porate grade of evidence and grade of expert opinion.
During the formulation of recommendations for manage-
ment (diagnosis, treatment and follow-up) of rhinosinusitis, all 
potential benefits, side effects and risks will be considered and 
clearly outlined, where necessary with supporting data. The 
grade of recommendation will also reflect these considerations, 
which was an effective way of presenting recommendations in 
EPOS2012. 
Results of literature reviews and summaries of the relevant 
evidence base will be clearly presented to back up all recom-
mendations. A complete reference list and bibliography will 
be provided to ensure that readers can access the evidence on 
which our recommendations are based, and to demonstrate the 
extent of our research. 
Review and updates
The EPOS2020 position paper will be subject to a full external 
review by experts from a variety of specialties prior to publi-
cation for the purposes of quality assurance. We will take into 
account feedback from reviewers representing different com-
munities in the world and different stakeholders (as mentioned 
above) on draft recommendations, applicability and feasibility 
when formulating the final document. A list of reviewers will be 
supplied as an appendix to the final document. A description 
of the methods for conducting the external review, along with 
recommendations from reviewers and outcomes of the review 
will be presented in an ‘External Review’ appendix.
The European Rhinologic Society has produced position papers 
on rhinosinusitis in 2007 and 2012 [following on from the first 
European Position Paper on Rhinosinusitis and Nasal Polyps 
(EP3OS) initiated by the European Academy of Allergology and 
Clinical Immunology in 2005] (16, 18, 19). EPOS2020 will be the latest 
iteration of this. We expect to update the position paper again 
after another 5 to 6 year interval. However, the scope of the gui-
deline may need to change in that time as the body of research 
into rhinosinusitis and its associated conditions continues to 
grow. With this in mind, following publication of EPOS2020, we 
will conduct a full review to measure uptake of our recommen-
dations and the overall impact of the guidelines.
Clarity of presentation
All recommendations in EPOS2020 will be presented clearly. 
Levels of evidence will be presented in tables (as in EPOS2012) 
and recommended diagnosis, treatment and referral pathways 
will be presented in straightforward, accessible diagrams (as in 
EPOS2012). We will make it clear which target users and popu-
lation the recommendation is targeted at / applicable to and 
explain the intended outcome of the recommendation, along 
with any associated caveats and risks. Where evidence and 
results are uncertain this will be clearly explained, and relevant 
recommendations will be formulated accordingly.
All options for the screening, prevention and management 
(including treatment, diagnosis and follow-up) of rhinosinusitis 
will be presented clearly in EPOS2020. Recommendations on 
these options will be graded based on the available evidence 
and when evidence is limited, based on expert opinions using 
Delphi rounds. Each option will be considered as relevant to the 
most applicable target population and target user. For example, 
in EPOS2012 a full section of the guideline was dedicated to pre-
senting evidence-based schemes for diagnosis and treatment 
of ARS and CRS in adult and paediatric populations and for ENT 
specialists and primary care practitioners.
Specific recommendations for diagnosis and treatment of 
each aspect of rhinosinusitis covered by the guideline will be 
summarised clearly, along with recommended areas for further 
research.
In addition to a section of the guideline presenting our recom-
mendations in clear algorithms, we will make several ‘Pocket 
Guide’ versions of EPOS2020 aimed at different stakeholders 
(otorhinolaryngologists, pharmacists, patients, primary care, 
other non-ENT specialists), translated into as many languages as 
possible. This was very successful for EPOS2007 and EPOS2012 
as a way of presenting our key recommendations and ma-
nagement schemes in an accessible format for target users. We 
intend to develop this further with an interactive version of the 
guideline after publication (‘wiki EPOS’), featuring extra links, 
videos, interactive flowcharts. This will be available online, and 
potentially as an easily accessible ‘EPOS app’. We feel that an app 
version would be particularly relevant to our target population, 
as a way of empowering patients – directing people through the 
available technologies and treatments.
Recommendations and applicability
The main facilitators and barriers to applying the EPOS2020 
guideline will be explored and reviewed, with feedback from 
key stakeholders. Although entitled ‘European’, which reflects 
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will be derived from our key recommendations. For example, 
number, frequency and duration of symptoms. This will enable 
the application and use of the guideline to be monitored and 
evaluated.
Editorial independence
Although funded in large part by the European Rhinologic Soci-
ety, Rhinology Journal, EUFOREA and the Rhinology Foundation 
and involving many of its members, EPOS2020 will be an inter-
national endeavour with contributions from a wide range of 
associated expert specialists who will analyse the latest research 
into rhinosinusitis and present up-to-date recommendations 
to all target users and populations. The views and interests of 
the ERS and other external sources of funding will not have any 
impact on our final recommendations, and this will be clearly 
stated in the final document.
There will be a large group of key stakeholders involved in the 
development of the EPOS2020 position paper. The competing 
interests of all guideline development group members will be 
recorded and any potential impact on the development of the 
guideline and our final recommendations will be addressed.
Conclusion
Patients with rhinosinusitis deserve the best possible manage-
ment of their disease. We hope this article acts as a useful star-
ting-off point for EPOS2020 and provides a detailed summary of 
our planned research strategy and methodologies. Our aim is for 
the next European Position Paper on Rhinosinusitis to promote 
better-informed decision-making by patients, members of the 
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its origin, the position paper is intended to be used around the 
world, and while it will not be possible to consider facilitators 
and barriers to using this document relevant to all specific geo-
graphical locations, we aim to ensure it is applicable to a wide 
range of healthcare systems. We will therefore explore care path-
ways relevant to a broad range of geographical locations and 
healthcare systems. Facilitators and barriers to diagnosis and 
treatment which apply to all target users and populations, such 
as lack of research / definitive conclusions, direct and indirect 
medical costs and resource implications will be explored in full. 
We expect to uncover other facilitators and barriers to applying 
the guideline through Delphi trials, and will clearly indicate how 
the outcomes of these trials influenced our conclusions and 
recommendations.
The EPOS2020 steering group is presently working on a com-
plete dissemination strategy. All members of the steering group 
have been asked to nominate important leaders in the field 
who we can be involved in the dissemination of the project. We 
want to include as many nationalities and relevant organisations 
as possible. International societies have been identified as an 
obvious route to target users. We also want to target student 
groups and non-specialist colleagues more specifically than 
may have happened with previous EPOS guidelines. Tools we 
hope to develop for putting the recommendations into practice 
include pocket guides aimed at different stakeholders, an in-
teractive online version of the guideline, an EPOS2020 App and 
patient education videos. We aim to raise the profile of the EPOS 
guideline even further using the Internet, social media and by 
collaborating with governmental organisations to bring about 
targeted interventions with measurable outcomes. The goal is 
to disseminate our research so widely that target stakeholders 
and users will have it delivered to them, rather than needing to 
seek it out.
Where they are identified, and where possible, resource 
implications of applying the recommendations will be descri-
bed. EPOS2020 will be an international position paper, so the 
resource implications of our key recommendations will vary 
for target users depending on their different geographical 
locations (this will be of particular consideration for developing 
countries). Where there is potential for our recommendations to 
have a significant impact on resources (good or bad), this will be 
clearly stated.
Management schemes will display clear criteria for diagnosis, 
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